Track ICON Public Limited Company — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

ICON Public Limited Company ICLR · Stock Open ICON Public Limited Company in new tab

194.65 USD
P/E
81.85
EPS
2.50
P/B
1.68
ROE
4.70
Beta
1.18
Target Price
231.29 USD
ICON Public Limited Company logo

ICON Public Limited Company

🧾 Earnings Recap – Q3 2026

ICON shares rose 17.8% after the company reported record net business wins and sequential improvement in gross margin, adjusted EBITDA, and EPS. Management said Q3 results were in line with its expectations, while the transcript provides no market-consensus comparison.

  • Net business wins reached a record $3.15 billion, up 51% year over year; net book-to-bill was 1.56x, the fourth consecutive quarter above 1.3x.
  • Gross margin improved 90 basis points sequentially. Adjusted EBITDA was $337 million, and adjusted EPS of $2.66 was up 4% from Q2.
  • Free cash flow was $300 million; ICON repurchased $400 million of shares and ended the quarter with $800 million in cash.
  • Commercial momentum included large-pharma strength, new and expanded midsized partnerships, and three preferred biotech partnerships.
  • Technology-enabled execution showed measurable gains: in-scope SDTM programming cycle times fell 28%, while study-startup throughput rose about 30% year to date.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 24, 2027
P/E81.85
EPS2.50
Book Value121.83
Price to Book1.68
Debt/Equity38.45
% Insiders0.456%
Growth
Revenue Growth-0.03%
Earnings Growth-0.63%
Estimates
Forward P/E17.64
Forward EPS11.60
Target Mean Price231.29

DCF valuation

Model fair value for ICON Public Limited Company (ICLR)
Result
Sign in to run the valuation for ICLR.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
17 analysts · consensus Buy · mean target 231.29 USD (low 180.00, high 268.00) · as of 11 Nov 2026
Low 180.00
Mean 231.29
High 268.00
Price 194.65
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

ICON Public Limited Company Logo ICON Public Limited Company Analysis (ICLR)

Ireland Health Care Official Website Stock

Is ICON Public Limited Company a good investment? ICON Public Limited Company (ICLR) is currently trading at 194.65 USD. Market analysts have a consensus price target of 231.29 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 81.85. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: ICON Public Limited Company is expected to release its next earnings report on Feb. 24, 2027. The market consensus estimate for Forward EPS is 11.60.

Investor FAQ

Does ICON Public Limited Company pay a dividend?

No, it does not currently pay a dividend.

What asset class is ICON Public Limited Company?

ICON Public Limited Company is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 24, 2027. The company currently has a trailing EPS of 2.50.

Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Exchange Ticker
NMS (United States) ICLR
FRA (Germany) IJF.F
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Oct. 24, 2006 2:1
Aug. 13, 2008 2:1
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion